Cure8
Limited source text

What Cure8 can confirm

What We Know

Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a case report related to Ulcerative colitis, Inflammatory bowel disease, JAK inhibitor, and Primary Sclerosing Cholangitis. Use the original source link for the full details.

What Is Not Available

The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationGastroenterology report
AuthorsMohammed Nabil Quraishi, Nadeen Omar, Hatim Taha +3 more
InstitutionDepartment of Gastroenterology, Sheikh Shakhbout Medical City, PureHealth, Abu Dhabi, United Arab Emirates.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 11, 2026, 12:00 AM
Content availableMetadata only

Conflict statement: M.N.Q. has received speaker fees from Johnson & Johnson, Takeda, AbbVie, Hikma, and Lilly, and consultancy fees from Johnson & Johnson, AbbVie and Lilly. Z.K. has received speaker fees from Johnson & Johnson, AbbVie and Lilly. All other authors do not have any relevant conflicts of interest to declare.

Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.

Related Reading

Browse latest news →